Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461370 · ClinicalTrials.gov registry record · Phase 1
Safety Study of SRX251 Capsules in Healthy Female Volunteers
A Phase 1 study, sponsored by Azevan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00461370: Completed Phase 1 study, sponsored by Azevan Pharmaceuticals.
NCT00461370 is a Phase 1 study that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00461370, a Phase 1 study, has completed, sponsored by Azevan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of SRX251 when given orally. The amount of SRX251 in the blood will also be measured. Healthy women, ages 18-50 years who have been surgically sterilized by tubal ligation, will be enrolled in this study.
Interventions
- DRUG SRX251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461370
The ClinicalTrials.gov registry entry for NCT00461370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SRX251 is the first listed.
NCT00461370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461370 about?
NCT00461370 is a clinical study titled "Safety Study of SRX251 Capsules in Healthy Female Volunteers". The purpose of this study is to determine the safety of SRX251 when given orally. The amount of SRX251 in the blood will also be measured. Healthy women, ages 18-50 years who have been surgically sterilized by tubal ligation, will be enrolled in this study.
What is the current status of trial NCT00461370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2007-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00461370?
The interventions under investigation include: SRX251 (DRUG).
Who is sponsoring clinical trial NCT00461370?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.